Windward Bio
Summary active Updated May 5, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Windward Bio is a Basel, Switzerland-based clinical-stage biotechnology company developing long-acting therapies for advanced immunological conditions 1. The company was founded in January 2025 by Luca Santarelli, MD, who serves as CEO and Board Chair 1 2. Its lead program is WIN378, an ultra long-acting anti-TSLP monoclonal antibody in Phase 2/3 development for asthma with planned Phase 2 studies in COPD; the pipeline also includes WIN027, a long-acting anti-TSLPxIL-13 bispecific in Phase 1 1. On May 4, 2026, Windward Bio announced a $165M crossover financing led by OrbiMed, bringing total funding raised since launch to $365M 1 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2025-01-10 | Series A | $200M | Omega Funds, RTW Investments | Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Qiming Venture Partners, Quan Capital, Pivotal bioVenture Partners 3 |
| 2026-05-04 | Crossover | $165M | OrbiMed | RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, Pivotal bioVenture Partners 1 2 |
What Investors Say
No independently sourced investor quotes found.
What Founders Say
Luca Santarelli, MD, Founder and CEO of Windward Bio: “We are excited to expand our shareholder base of top-tier investors…This financing further strengthens our balance sheet and allows us to advance our programs of next-generation therapies for patients living with serious respiratory and dermatological diseases.” 1
Sources
-
GlobeNewswire, “Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential,” May 4, 2026. Accessed May 2026. https://www.globenewswire.com/news-release/2026/05/04/3286605/0/en/Windward-Bio-Announces-165M-Crossover-Financing-to-Advance-Pipeline-of-Long-Acting-Immunology-Therapies-With-Best-in-Disease-Potential.html↩↩↩↩↩↩
-
Novo Holdings, “Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential,” May 2026. Accessed May 2026. https://novoholdings.dk/news/novo-holdings-joins-165-million-crossover-financing-for-windward-bio-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential↩↩↩
-
GlobeNewswire, “Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD,” January 10, 2025. Accessed May 2026. https://www.globenewswire.com/news-release/2025/01/10/3007703/0/en/Windward-Bio-Launches-With-200-Million-Series-A-Financing-to-Develop-Phase-2-Ready-Long-Acting-Anti-TSLP-Antibody-With-Best-in-Class-Potential-in-Asthma-and-COPD.html↩